Grant: CIHR Fellowship
University of Toronto
$90,000.00
High-Throughput Heart-on-a-Chip Platform for Studies of SARS-CoV-2 Induced Myocardial Injury
FY 2020-21
Summary
Recent study reported that 78% of the patients recovered from COVID-19 have cardiac involvement and 60% of the patients have ongoing myocardial inflammation based on cardiac magnetic resonance imaging. However, the direct contribution of SARS-CoV-2 infection on the beating cells types of the heart, cardiomyocytes, versus supporting cells that makeup the blood vessels and the matrix as well as immune cells homing to the heart after the infection are not well understood. Human stem cell derived heart-on-a-chip models afford the most direct and efficient route for answering these questions. My preliminary data collected in the CL3 facility demonstrate profound and progressive loss of contractile ability in my heart-on-a-chip platform upon SARS-CoV-2 infection. Stem cell based heart-on-a-chip model is additionally unique as it enables us to systematically study infection on different cell types that make up the heart, an experiment that is not possible in vivo.
I will first scale up the production of the heart-on-a-chip platform using 3D printing. I will situate this platform in a 24 well plate, a setting that is suitable for working in biohazard level 3 facility. After infecting the human heart tissue with SARS-CoV-2, I will non-invasively measure how the contractile force changes with time. At the same time, I can collect culture media and determine the extent of inflammation. Through electron microscopy, I will visualize the virus in the human heart tissue.
Therapies for covid19 infected heart currently do not exist. I hypothesize that extracellular vesicles derived from healthy cells could represent a viable biological therapy. These consist of a rich mixture of micro RNAs and proteins that are known to be able to protect the heart in other settings, such as loss of oxygen. I will isolate these EVs from healthy cells and apply them to the infected heart-on-a-chip to study preservation of beating function and subsequent improvement.
Department
Program
CIHR Fellowship
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
441364
Name
Wu Qinghua
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
High-Throughput Heart-on-a-Chip Platform for Studies of SARS-CoV-2 Induced Myocardial Injury
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$90,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
3d Printing; Cardioprotective Therapy; Heart-On-A-Chip; Myocarditis; Sars-Cov-2
Abstract
Recent study reported that 78% of the patients recovered from COVID-19 have cardiac involvement and 60% of the patients have ongoing myocardial inflammation based on cardiac magnetic resonance imaging. However, the direct contribution of SARS-CoV-2 infection on the beating cells types of the heart, cardiomyocytes, versus supporting cells that makeup the blood vessels and the matrix as well as immune cells homing to the heart after the infection are not well understood. Human stem cell derived heart-on-a-chip models afford the most direct and efficient route for answering these questions. My preliminary data collected in the CL3 facility demonstrate profound and progressive loss of contractile ability in my heart-on-a-chip platform upon SARS-CoV-2 infection. Stem cell based heart-on-a-chip model is additionally unique as it enables us to systematically study infection on different cell types that make up the heart, an experiment that is not possible in vivo.
I will first scale up the production of the heart-on-a-chip platform using 3D printing. I will situate this platform in a 24 well plate, a setting that is suitable for working in biohazard level 3 facility. After infecting the human heart tissue with SARS-CoV-2, I will non-invasively measure how the contractile force changes with time. At the same time, I can collect culture media and determine the extent of inflammation. Through electron microscopy, I will visualize the virus in the human heart tissue.
Therapies for covid19 infected heart currently do not exist. I hypothesize that extracellular vesicles derived from healthy cells could represent a viable biological therapy. These consist of a rich mixture of micro RNAs and proteins that are known to be able to protect the heart in other settings, such as loss of oxygen. I will isolate these EVs from healthy cells and apply them to the infected heart-on-a-chip to study preservation of beating function and subsequent improvement.
Competitiondate
202012
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Wu, Qinghua
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $90,000~ $0~